Study to Optimize the Quality of Samples for Cell-mediated Immunity (CMI) in ART-naïve HIV-1-infected Subjects
14. april 2020 opdateret af: GlaxoSmithKline
Optimizing the Quality of Samples Used for the Evaluation of Cell-mediated Immune (CMI) Responses in Antiretroviral Therapy (ART)-naïve Human Deficiency Virus Type 1 (HIV-1)-Infected Subjects
The purpose of this study is to investigate a combined set of parameters deemed to impact the quality of CMI analyses in terms of the proportion of viable lymphocytes in antiretroviral therapy-naïve HIV-1 infected subjects.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This study will address the respective and combined impact of (i) timing between blood collection and peripheral blood mononuclear cells (PBMC) processing ["time-to-process"] and (ii) timing of PBMC resting before stimulation ["resting -time"].
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
22
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Gent, Belgien, 9000
- GSK Investigational Site
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 55 år (Voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
All subjects must satisfy all the following criteria at study entry:
- Subjects who the Investigator believes can and will comply with the requirements of the protocol.
- Written informed consent obtained from the subject prior to any study procedure.
- A male or female between and including 18 and 55 years of age at the time of enrollment.
- Confirmed HIV-1 infection.
- ART-naïve and not eligible for ART treatment as per established guidelines. Subjects must never have received ART after HIV diagnosis, including lamivudine used for chronic hepatitis B infection. The exception to this is short-term ART for prevention of mother-to-child transmission (PMTCT) which must have been completed at least 360 days prior to enrollment.
- Viral load level between and including 2,000 and 100,000 copies/mL at screening.
- CD4+ T cell count >500 cells/mm3 at screening.
If the subject is female, she must be of non-childbearing potential, i.e., have a current tubal ligation, hysterectomy, ovariectomy or be post-menopausal. Female subjects of childbearing potential may be enrolled in the study, if the subject:
- has practiced adequate contraception for 30 days prior to vaccination, and
- has a negative pregnancy test at screening, and
- has agreed to continue adequate contraception during the entire study period.
Exclusion Criteria:
The following criteria should be checked at the time of study entry. If any exclusion criterion applies, the subject must not be included in the study:
- Infection with HIV-2. This includes subjects with dual infection with HIV-1/HIV-2.
- Planned use of any hematotoxic product during the study period.
- Planned use of any investigational or non-registered product during the study period.
- Acute or chronic, clinically relevant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination, serology and/or medical history at screening.
- Grade 3 or grade 4 laboratory abnormalities, as defined by Division of AIDS (DAIDS) grading table, at screening.
- Any condition which, in the opinion of the Investigator, could compromise the subject's adherence to the study protocol.
- Planned administration of a vaccine not foreseen by the study protocol during the period starting 30 days before the Sample Collection Visit (Visit 2). Vaccine can be administered as after sampling in Visit 2.
- Pregnant or lactating female.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: HIV-1 Group
Antiretroviral Therapy-naïve HIV1-infected subjects, aged 18 to 55 years, from whom samples for cell-mediated immunity (CMI) were collected.
No investigational vaccine was administered.
|
Blood samples will be collected in all subjects at two time points, at the Screening Visit (Day 0) and at the Sample Collection Visit (Day 15)
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Lymphocytes Viability Prediction (LOGIT Transformed) in CMI Samples Post-overnight Incubation Time Before Intracellular Cytokine Staining (ICS): "Intercept" Parameter Estimate of the Prediction Model - Condition "None" Resting Time Not Included
Tidsramme: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=2h, 6h or 18h ["none" resting time not included]) conditions to select the best combination of these two parameters to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10^P/(1 + 10^P)*100 with P for Prediction.The optimum of the viability was predicted as P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + a*a*TP*TP + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the 3 first primary outcomes.
And a and b are log-transformed parameters corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
This outcome is presenting the intercept i.e. expected mean value of Prediction when "TP" and "RT" = 0.
The optimum of this Design of Experiment is presented in outcome 4.
|
At Day 15 (sample collection visit)
|
|
Lymphocytes Viability Prediction (LOGIT Transformed Estimate) in CMI Samples Post-overnight Incubation Time Before ICS: Time to Process and Resting Time Parameter Estimates of the Prediction Model - Condition "None" Resting Time Not Included
Tidsramme: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=2h, 6h or 18h ["none" resting time not included]) conditions to select the best combination of these two parameters to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10 ^ P / (1 + 10 ^ P) * 100 with P for Prediction.The optimum of the viability was predicted as P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + a*a*TP*TP + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the 3 first primary outcomes.
And a and b are log-transformed parameters corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
This outcome is presenting "TP" and "RT" estimates expressed as log(hours).
The optimum of this Design of Experiment (DOE) is presented in outcome 4.
|
At Day 15 (sample collection visit)
|
|
Lymphocytes Viability Prediction (LOGIT Transformed Estimate) in CMI Samples Post-overnight Incubation Time Before ICS: TP*RT, TP*TP and RT*RT Parameter Estimates of the Prediction Model - Condition "None" Resting Time Not Included
Tidsramme: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=2h, 6h or 18h ["none" resting time not included]) conditions to select the best combination of these two parameters to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10 ^ P / (1 + 10 ^ P) * 100 with P for Prediction.The optimum of the viability was predicted as P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + a*a*TP*TP + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the 3 first primary outcomes.
And a and b are log-transformed parameters corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
This outcome is presenting TP*RT, TP*TP and RT*RT estimates expressed as log(hours^2).
The optimum of this DOE is presented in outcome 4.
|
At Day 15 (sample collection visit)
|
|
Lymphocytes Viability Prediction (LOGIT Transformed Estimate) in CMI Samples Post-overnight Incubation Time Before ICS: Optimum Mean Cell Viability Estimate by the Prediction Model - Condition "None" Resting Time Not Included
Tidsramme: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=2h, 6h or 18h ["none" resting time not included]) conditions to select the best combination of these two parameters to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10 ^ P / (1 + 10 ^ P) * 100 with P for Prediction.The optimum of the viability was predicted as P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + a*a*TP*TP + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the 3 first primary outcomes.
And a and b are log-transformed parameters corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
The optimum predicted mean cell viability of this Design of Experiment is presented in this outcome and expressed as percentage.
|
At Day 15 (sample collection visit)
|
|
Lymphocytes Viability Prediction (Non-transformed Estimate) in CMI Samples Post-overnight Incubation Time Before ICS: "Intercept" Parameter Estimate of the Prediction Model - Condition "None" Resting Time Included
Tidsramme: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=0h) conditions in order to select the best combination of these two parameters with the aim to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10 ^ P / (1 + 10 ^ P) * 100 with P for Prediction.
The optimum of the viability was predicted as follows.
P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the primary outcomes 5, 6 and 7.
And "a" and "b" are parameters (hour) corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
This outcome is presenting the intercept i.e. expected mean value of Prediction when "TP" and "RT" = 0.
The optimum of this Design of Experiment is presented in outcome 8.
|
At Day 15 (sample collection visit)
|
|
Lymphocytes Viability Prediction (Non-transformed Estimate) in CMI Samples Post-overnight Incubation Time Before ICS: Time to Process and Resting Time Parameter Estimates of the Prediction Model - Condition "None" Resting Time Included
Tidsramme: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=0h) conditions in order to select the best combination of these two parameters with the aim to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10 ^ P / (1 + 10 ^ P) * 100 with P for Prediction.
The optimum of the viability was predicted as follows.
P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the primary outcomes 5, 6 and 7.
And "a" and "b" are parameters (hour) corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
This outcome is presenting "TP" and "RT" estimates expressed as log(hours).
The optimum of this Design of Experiment (DOE) is presented in outcome 8.
|
At Day 15 (sample collection visit)
|
|
Lymphocytes Viability Prediction (Non-transformed Estimate) in CMI Samples Post-overnight Incubation Time Before ICS: TP*RT and RT*RT Parameter Estimates of the Prediction Model - Condition "None" Resting Time Included
Tidsramme: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=0h) conditions in order to select the best combination of these two parameters with the aim to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10 ^ P / (1 + 10 ^ P) * 100 with P for Prediction.
The optimum of the viability was predicted as follows.
P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the primary outcomes 5, 6 and 7.
And "a" and "b" are parameters (hour) corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
This outcome is presenting TP*RT and RT*RT estimates expressed as log(hours^2).
The optimum of this DOE is presented in outcome 8.
|
At Day 15 (sample collection visit)
|
|
Lymphocytes Viability Prediction (Non-transformed Estimate) in CMI Samples Post-overnight Incubation Time Before ICS: Optimum Mean Cell Viability Estimates by the Prediction Model -Condition "None" Resting Time Included.
Tidsramme: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=0h) conditions in order to select the best combination of these two parameters with the aim to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10 ^ P / (1 + 10 ^ P) * 100 with P for Prediction.
The optimum of the viability was predicted as follows.
P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the primary outcomes 5, 6 and 7.
And "a" and "b" are parameters (hour) corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
The optimum predicted mean cell viability of this Design of Experiment is presented in this outcome and expressed as percentage.
|
At Day 15 (sample collection visit)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Viable Lymphocytes in the CMI Samples, Post-overnight Incubation (Classic) Before ICS and Post-6 Hour Incubation Before ICS
Tidsramme: A Day 15 (sample collection visit)
|
The percentage of viable lymphocytes was determined by Forward Scatter/Side Scatter (FSC/SSC) and LIVE/DEAD gating during flow cytometry analysis for each incubation of time-to-time process (TP) = 2h, 7h and 24 h and resting time (RT) = 18h for the comparison of resting time = 18h and classic incubation time versus resting time = 18h and post-6h incubation time.
|
A Day 15 (sample collection visit)
|
|
Magnitude of HIV-1 RT Specific Cluster of Differentiation 40 Ligand (CD40L+) CD4+ T Cell Responses in the CMI Samples Post-overnight ICS/Post 6 Hour ICS, Expressing at Least One Cytokine
Tidsramme: At Day 15 (sample collection visit)
|
Data were collected but could not be reported as data were below level of detection.
|
At Day 15 (sample collection visit)
|
|
Magnitude of HIV-RT Specific (Background Reduced) CD8+ T Cell Responses in the CMI Samples Post-overnight ICS/Post 6 Hour ICS, Expressing at Least One Cytokine
Tidsramme: At Day 15 (sample collection visit)
|
HIV-RT specific responses of CD8+ T cells expressing at least one cytokine, among: Interleukin-2 (IL-2), Interferon-gamma (IFN-g) and Tumor necrosis factor alpha (TNF-a),after stimulation with HIV-1 peptide pools for time-to-process (TP) (2, 7, 24 hours) and resting time (RT) (0,2,6,18 hours) post-overnight ICS and for time-to-process (7 hours) and resting time (18 hours) post 6 hours ICS.
|
At Day 15 (sample collection visit)
|
|
Number of Subjects With Serious Adverse Events (SAEs)
Tidsramme: During the whole study period (From Day 0 to Day 15)
|
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitali-zation or prolongation of hospitalization or result in disability/incapacity.
|
During the whole study period (From Day 0 to Day 15)
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
25. juni 2012
Primær færdiggørelse (Faktiske)
30. oktober 2012
Studieafslutning (Faktiske)
30. oktober 2012
Datoer for studieregistrering
Først indsendt
31. maj 2012
Først indsendt, der opfyldte QC-kriterier
31. maj 2012
Først opslået (Skøn)
4. juni 2012
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
24. april 2020
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
14. april 2020
Sidst verificeret
1. april 2020
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Andre undersøgelses-id-numre
- 116329
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med AIDS
-
University Hospital, GrenobleSociété Française d'Anesthésie et de RéanimationAfslutteteFast Diagnosis Performance in Guiding First Aid Resuscitation and HemostasisFrankrig
-
Pierre Fabre MedicamentAktiv, ikke rekrutterendeLymfoproliferative lidelser | Leiomyosarkom | Stamcelletransplantationskomplikationer | Komplikationer ved transplantation af faste organer | Epstein-Barr-virus (EBV)-associerede sygdomme | EBV+ post-transplantation lymfoproliferativ sygdom (EBV+ PTLD) | Allogen hæmatopoietisk celletransplantation | EBV+... og andre forholdForenede Stater, Østrig, Belgien, Frankrig, Italien, Spanien, Det Forenede Kongerige
-
Atara BiotherapeuticsIkke længere tilgængeligLymfoproliferative lidelser | Stamcelletransplantationskomplikationer | Epstein-Barr Virus (EBV) infektioner | EBV+ Associeret lymfom | EBV+ Associated Post-transplant lymfoproliferativ sygdom (EBV+ PTLD) | Epstein-Barr Viremia | Lymfom, AIDS-relateret | Epstein-Barr-virus-associeret lymfoproliferativ... og andre forhold
Kliniske forsøg med Blood sample collection
-
Hillel Yaffe Medical CenterUkendt
-
Centro Hospitalar do PortoEIT Health; Promptly HealthAfsluttet
-
Midwest Heart & Vascular SpecialistsRekrutteringAL Amyloidose | Amyloid | Hjerte amyloidose | Amyloidose Hjerte | Systemisk amyloidose | ATTR Amyloidose vildtype | Infiltrativ kardiomyopati, amyloidForenede Stater
-
Terumo BCTAfsluttetEnhedsvalidering af in-vivo ydeevneForenede Stater
-
Bettina MittendorferRekrutteringHjertefejl | Diabetes | Hyperparathyroidisme | Sarkopeni | Osteoporose | Iskæmisk hjertesygdom | Kakeksi | Osteopeni | Hypoparathyroidisme | Cystisk fibrose (CF) | Aterosklerotisk sygdom | Kronisk nyresygdom (CKD) | Fedme og fedme-relaterede medicinske tilstande | MOSEForenede Stater
-
Massachusetts General HospitalRekruttering
-
University of FloridaTilmelding efter invitation
-
Applied Biology, Inc.Trukket tilbageAndrogenetisk alopeci | Hårtab | Hårtab/skaldethed | Kvindelig mønster skaldethedForenede Stater
-
Children's Hospital of Fudan UniversityGuangzhou Women and Children's Medical Center; Maternal and Child Health... og andre samarbejdspartnereRekrutteringNeonatal encefalopati | Mistænkt neonatal encefalopatiKina
-
Changhai HospitalWest China Hospital; Tongji Hospital; Ruijin Hospital; Wuhan Union Hospital... og andre samarbejdspartnereIkke rekrutterer endnuGastroøsofageal reflukssygdom